>

Research in Motion (RIMM): Buy or sell after fourth-quarter results?

Yesterday we reported the disappointing Research in Motion (RIMM) fourth-quarter results, and we would love to know if you would buy or sell now.

DailyFinance

online pharmacy purchase mobic without prescription with best prices today in the USA

gave a summary of net income, which came is at $1.27 per share a double-digit growth compared to the relevant period, investors and analysts sold stock during Wednesday’s after-hours session and a “Goldman Sachs downgrade of the share to sell from neutral Thursday morning and RIMM is selling off some 5% in pre-market trading” according to BloggingStocks.

Just like Market Watch

online pharmacy tamiflu over the counter with best prices today in the USA

we said that the RIM earnings jump was disappointing, the question is “Is it best to buy or sell now or should we just for the price action to let us know where the stocks might go?”

Please do let us know more about this, what would you do? Please vote below, we will keep you up-to-date about these stocks and shares.

[poll id=”157″]

Live Comment

Your email address will not be published.